GSK's antiviral drug has annual sales of $1.2 billion in the US.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has obtained US Food and Drug Administration (FDA) marketing approval for its generic version of GlaxoSmithKline plc's (NYSE; LSE: GSK) Valtrex, an antiviral drug.
According to IMS sales data, brand Valtrex has annual sales of $1.2 billion in the US.
Teva's share price rose 0.6% in premarket trading on Nasdaq today to $56.01, and rose 3.5% on the TASE to NIS 217.10, the only share on the Tel Aviv 25 Index to buck today's slide.
Published by Globes [online], Israel business news - www.globes-online.com - on May 25, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010